FK 565 | CAS#79335-75-4

MedKoo Cat#: 535038 | Name: FK 565

Description:

WARNING: This product is for research use only, not for human or veterinary use.

FK 565 is a synthetic cpd; also immunoactive peptide isolated from Streptomyces active against multiplication of HSV-1 & HSV-2 virus.

Chemical Structure

FK 565

CAS#79335-75-4

Theoretical Analysis

MedKoo Cat#: 535038

Name: FK 565

CAS#: 79335-75-4

Chemical Formula: C22H38N4O9

Exact Mass: 502.2639

Molecular Weight: 502.57

Elemental Analysis: C, 52.58; H, 7.62; N, 11.15; O, 28.65

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

FK 565; FK-565; FK565

IUPAC/Chemical Name

D-Alanine, N-((R)-6-carboxy-N2-(N-(1-oxoheptyl)-D-gamma-glutamyl)-L-lysyl)-

InChi Key

ZRWBSKCFKHSDHD-LVQVYYBASA-N

InChi Code

InChI=1S/C22H38N4O9/c1-3-4-5-6-10-17(27)26-16(22(34)35)11-12-18(28)25-15(9-7-8-14(23)21(32)33)19(29)24-13(2)20(30)31/h13-16H,3-12,23H2,1-2H3,(H,24,29)(H,25,28)(H,26,27)(H,30,31)(H,32,33)(H,34,35)/t13-,14-,15+,16-/m1/s1

SMILES Code

C[C@H](C(O)=O)NC([C@H](CCC[C@H](C(O)=O)N)NC(CC[C@H](C(O)=O)NC(CCCCCC)=O)=O)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 502.57 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Ahmed K, Turk JL. Effect of anticancer agents neothramycin, aclacinomycin, FK-565 and FK-156 on the release of interleukin-2 and interleukin-1 in vitro. Cancer Immunol Immunother. 1989;28(2):87-92. doi: 10.1007/BF00199107. PMID: 2783891. 2: Mine Y, Yokota Y, Wakai Y, Fukada S, Nishida M, Goto S, Kuwahara S. Immunoactive peptides, FK-156 and FK-565. I. Enhancement of host resistance to microbial infection in mice. J Antibiot (Tokyo). 1983 Aug;36(8):1045-50. doi: 10.7164/antibiotics.36.1045. PMID: 6415029. 3: Sodhi A, Basu S. Role of human blood monocytes in up-regulation of lymphokine (interleukin-2)-activated killer cell activity with cisplatin and FK-565. Nat Immun. 1992 Mar-Apr;11(2):105-16. PMID: 1498519. 4: Talmadge JE, Lenz B, Schneider M, Phillips H, Long C. Immunomodulatory and therapeutic properties of FK-565 in mice. Cancer Immunol Immunother. 1989;28(2):93-100. doi: 10.1007/BF00199108. PMID: 2521814. 5: Inamura N, Nakahara K, Kino T, Gotoh T, Kawamura I, Aoki H, Imanaka H, Sone S. Activation of tumoricidal properties in macrophages and inhibition of experimentally-induced murine metastases by a new synthetic acyltripeptide, FK-565. J Biol Response Mod. 1985 Aug;4(4):408-17. PMID: 4031951. 6: Chitko CG, Chapes SK, Thaler RC, Nelssen JL, Anderson GA, Clough ER, Blecha F. In vitro and in vivo evaluation of effects of a heptanoyl tripeptide, FK-565, on porcine macrophage and lymphocyte function. Am J Vet Res. 1991 Jan;52(1):169-73. PMID: 2021246. 7: Watanabe Y, Tawara S, Mine Y, Kikuchi H. Immunoactive peptides, FK 156 and FK 565. IV. Activation of mouse macrophages. J Antibiot (Tokyo). 1985 Dec;38(12):1781-7. doi: 10.7164/antibiotics.38.1781. PMID: 3005214. 8: Yokota Y, Wakai Y, Watanabe Y, Mine Y. Inhibitory effect of FK-565 alone and in combination with zidovudine on retroviral infection by Friend leukemia virus in mice. J Antibiot (Tokyo). 1988 Oct;41(10):1479-87. doi: 10.7164/antibiotics.41.1479. PMID: 3192497. 9: Yokota Y, Mine Y, Wakai Y, Watanabe Y, Nishida M, Goto S, Kuwahara S. Immunoactive peptides, FK-156 and FK-565. II. Restoration of host resistance to microbial infection in immunosuppressed mice. J Antibiot (Tokyo). 1983 Aug;36(8):1051-8. doi: 10.7164/antibiotics.36.1051. PMID: 6415030. 10: Inamura N, Sone S, Okubo A, Kunishige E, Nakanishi M, Ogura T. Tumor cytotoxicity of human monocyte membrane-bound interleukin-1 alpha induced by synergistic actions of interferon-gamma and synthetic acyltripeptide, FK-565. Cancer Immunol Immunother. 1989;28(3):164-70. doi: 10.1007/BF00204984. PMID: 2493987. 11: Mine Y, Watanabe Y, Tawara S, Yokota Y, Nishida M, Goto S, Kuwahara S. Immunoactive peptides, FK-156 and FK-565. III. Enhancement of host defense mechanisms against infection. J Antibiot (Tokyo). 1983 Aug;36(8):1059-66. doi: 10.7164/antibiotics.36.1059. PMID: 6630057. 12: Sodhi A, Basu S. Up-regulation of IL-2 induced lymphokine activated killer cell activity by cisplatin and FK-565: involvement of calcium ion. Immunol Lett. 1992 Apr;32(2):139-46. doi: 10.1016/0165-2478(92)90106-x. PMID: 1612637. 13: Murata K, Motomura Y, Tanaka T, Kanno S, Yano T, Onimaru M, Shimoyama A, Nishio H, Sakai Y, Oh-Hora M, Hara H, Fukase K, Takada H, Masuda S, Ohga S, Yamasaki S, Hara T. Calcineurin inhibitors exacerbate coronary arteritis via the MyD88 signalling pathway in a murine model of Kawasaki disease. Clin Exp Immunol. 2017 Oct;190(1):54-67. doi: 10.1111/cei.13002. Epub 2017 Jul 21. PMID: 28640392; PMCID: PMC5588765. 14: Weissmann N, Leyhausen G, Maidhof A, Tanaka W, Umezawa H, Müller WE. Mitogenic potentials of bestatin, amastatin, arphamenines A and B, FK-156 and FK-565 on spleen lymphocytes. J Antibiot (Tokyo). 1985 Jun;38(6):772-8. doi: 10.7164/antibiotics.38.772. PMID: 4019321. 15: Basu S, Sodhi A, Singh SM, Suresh A. Up-regulation of induction of lymphokine (IL-2)-activated killer (LAK) cell activity by FK-565 and cisplatin. Immunol Lett. 1991 Mar;27(3):199-204. doi: 10.1016/0165-2478(91)90151-y. PMID: 2060971. 16: Blaney BA, Hasan SI, Koe LA, Turk JL. The in vitro action of FK 565, bleomycin and cyclosporin A on different cell populations, with respect to the release of GM-CSF in the mouse. Int J Immunopharmacol. 1993 Nov;15(8):853-63. doi: 10.1016/0192-0561(93)90002-g. PMID: 7504660. 17: Schultz RM, Altom MG. Macrophage involvement in the antitumor activity of a synthetic acyltripeptide (FK-565) against experimental lung carcinoma metastases. J Immunopharmacol. 1986;8(4):515-28. doi: 10.3109/08923978609026503. PMID: 3543138. 18: Izumi S, Nakahara K, Gotoh T, Hashimoto S, Kino T, Okuhara M, Aoki H, Imanaka H. Antitumor effects of novel immunoactive peptides, FK-156 and its synthetic derivatives. J Antibiot (Tokyo). 1983 May;36(5):566-74. doi: 10.7164/antibiotics.36.566. PMID: 6192122. 19: Basu S, Sodhi A. Increased release of interleukin-1 and tumour necrosis factor by interleukin-2-induced lymphokine-activated killer cells in the presence of cisplatin and FK-565. Immunol Cell Biol. 1992 Feb;70 ( Pt 1):15-24. doi: 10.1038/icb.1992.3. PMID: 1639431. 20: Kolodziejczyk AM, Kolodziejczyk AS, Stoev S. New convenient synthesis of immunostimulating peptides containing meso-diaminopimelic acid. Syntheses of FK-565 and FK-156. Int J Pept Protein Res. 1992 Apr;39(4):382-7. doi: 10.1111/j.1399-3011.1992.tb01598.x. PMID: 1428528.

View History

ACH-806

MedKoo CAT#: 524130

CAS#: 870142-71-5